The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Apr. 24, 3:16 AM

Slide #14. Sorrento Therapeutics, Inc. Secondary Offering

Company: Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
Date announced: 4/12/2017
Shares Offered: 23,625,084
Date of Pricing: 4/13/2017
Price Per Share: $2.00
Secondary Offering Details: Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Sorrento will grant the underwriter an option exercisable, in whole or in part, in the sole discretion of the underwriter, to purchase additional shares, for a period of up to 30 days. All of the shares will be offered and sold by Sorrento. -updated 4/13- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, today announced the pricing of its public offering of 23,625,084 shares of its common stock at a price to the public of $2.00 per share. In addition, Sorrento has granted the underwriters an option exercisable, in whole or in part, in the sole discretion of the underwriters, to purchase up to 3,543,763 additional shares, for a period of up to 30 days. All of the shares will be offered and sold by Sorrento. Henry Ji, Ph.D., Sorrento's President and Chief Executive Officer and a member of Sorrento's board of directors, is purchasing shares in the offering.

Sorrento Therapeutics is a biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics. Co.'s primary therapeutic focus is oncology, including the treatment of chronic cancer pain. Co. is also developing therapeutic products for other indications, including immunology and infectious diseases. Co. has seveal clinical development programs underway: Chimeric Antigen Receptor-T cell (CAR-T) programs for solid tumors; resiniferatoxin (RTX), a non-opiate, ultra-potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease; and biosimilar/biobetter antibodies clinical development programs.

SRNE SEC Filing Email Alerts Service

Open the SRNE Page at The Online Investor »

Company Name:  Sorrento Therapeutics Inc
Website:  www.sorrentotherapeutics.com
Sector:  Biotechnology
Number of ETFs Holding SRNE:  12
Total Market Value Held by ETFs:  $1.52M
Total Market Capitalization:  $84.00M
% of Market Cap. Held by ETFs:  1.81%
 

Open the SRNE Page at The Online Investor (in a new window) »

April 24, 2017    3:16 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.